País: Canadá
Língua: inglês
Origem: Health Canada
CALCIUM (CALCIUM CARBONATE); ETIDRONATE DISODIUM
TEVA CANADA LIMITED
M05BB01
ETIDRONIC ACID AND CALCIUM, SEQUENTIAL
500MG; 400MG
KIT
CALCIUM (CALCIUM CARBONATE) 500MG; ETIDRONATE DISODIUM 400MG
ORAL
14TABS-76TABS
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0241781001; AHFS:
CANCELLED PRE MARKET
2015-08-06
_NTP-ETIDRONATE CALCIUM Page 1 of 32 _ PRODUCT MONOGRAPH PR NTP-ETIDRONATE CALCIUM Etidronate Disodium tablets USP 400 mg and Calcium Carbonate tablets USP 1,250 mg calcium carbonate per tablet 500 mg elemental calcium BONE METABOLISM REGULATOR Teva Canada Ltd. 30 Novopharm Court Toronto, Ontario Canada, M1B 2K9 Submission Control No: 166000 Date of Preparation: July 19, 2013 _NTP-ETIDRONATE CALCIUM Page 2 of 32 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ......................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ........................................................................................................... 7 DRUG INTERACTIONS ........................................................................................................... 8 DOSAGE AND ADMINISTRATION ....................................................................................... 9 OVERDOSAGE ....................................................................................................................... 10 ACTIONS AND CLINICAL PHARMACOLOGY ................................................................. 11 STORAGE AND STABILITY ................................................................................................. 14 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 14 PART II: SCIENTIFIC INFORMATION ............................................................................... 16 PHARMACEUTICAL INFORMATION ....................................................................... Leia o documento completo